The price of Bolt Biotherapeutics Inc. (NASDAQ:BOLT) shares last traded on Wall Street fell -1.54% to $1.28.
Based on available information, 6 analysts follow Bolt Biotherapeutics Inc. (NASDAQ:BOLT). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $4.00, we find $7.00. Given the previous closing price of $1.30, this indicates a potential upside of 438.46 percent. BOLT stock price is now -5.58% away from the 50-day moving average and -31.90% away from the 200-day moving average. The market capitalization of the company currently stands at $50.41M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 2 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $6.40 as their price target over the next twelve months.
On March 02, 2021, SVB Leerink recently initiated its ‘Outperform’ rating on the stock quoting a target price of $36, while ‘Stifel’ rates the stock as ‘Buy’.
In other news, Novo Holdings A/S, 10% Owner sold 800,000 shares of the company’s stock on Jul 13. The stock was sold for $1,600,000 at an average price of $2.00. Upon completion of the transaction, the 10% Owner now directly owns 3,703,991 shares in the company, valued at $4.74 million. Insiders disposed of 800,000 shares of company stock worth roughly $1.02 million over the past 1 year. A total of 9.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BOLT stock. A new stake in Bolt Biotherapeutics Inc. shares was purchased by ORBIMED ADVISORS LLC during the first quarter worth $987,000. CAAS CAPITAL MANAGEMENT LP invested $149,000 in shares of BOLT during the first quarter. In the first quarter, PRIVIUM FUND MANAGEMENT (UK) LTD acquired a new stake in Bolt Biotherapeutics Inc. valued at approximately $149,000. BAILARD, INC. acquired a new stake in BOLT for approximately $59,000. PARAMETRIC PORTFOLIO ASSOCIATES LLC purchased a new stake in BOLT valued at around $23,000 in the second quarter. In total, there are 89 active investors with 68.00% ownership of the company’s stock.
A candlestick chart of Bolt Biotherapeutics Inc. (NASDAQ: BOLT) showed a price of $1.3000 on Wednesday morning. During the past 12 months, Bolt Biotherapeutics Inc. has had a low of $1.23 and a high of $5.16. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.20, and a quick ratio of 7.20. The fifty day moving average price for BOLT is $1.3556 and a two-hundred day moving average price translates $1.8795 for the stock.
The latest earnings results from Bolt Biotherapeutics Inc. (NASDAQ: BOLT) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.61, beating analysts’ expectations of -$0.68 by 0.07. This compares to -$0.63 EPS in the same period last year. The company reported revenue of $2.11 million for the quarter, compared to $0.75 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 180.85 percent. For the current quarter, analysts expect BOLT to generate $980k in revenue.
Bolt Biotherapeutics Inc.(BOLT) Company Profile
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
